Bernstein is positive on AstraZeneca taking the lead in the ATTR-CM cardiac market

Overview

This report is a deep dive by Bernstein on ATTR, particularly the ATTR-CM market, with AstraZeneca as the main investment focus. It argues that ATTR-CM has high unmet medical need, low diagnosis rates, and substantial market expansion potential, and that AstraZeneca could lead the long-term peak market by building a complete treatment portfolio through Wainua, cliramitug, and commercialization rights for Attruby in Japan.

Core views

The core thesis is that despite Amvuttra by Alnylam already being strongly launched, the market still underestimates AstraZeneca’s portfolio advantage in ATTR-CM, rare-disease execution, and the upside potential of key clinical data. Bernstein believes AZN’s ATTR revenue forecasts will be a positive surprise source, with 2036e AZN ATTR sales around $10bn and a potential upside of about 10% versus consensus group sales.

Analysis framework

The report reassesses long-term sales and share of Wainua, cliramitug, Amvuttra, nucresiran, Vyndaquel, and Attruby by combining disease-mechanism decomposition, treatment-paradigm comparison, KOL interviews, rare-disease market expansion precedents, bottom-up patient count modeling, and top-down validation using U.S. prescription data.

Methodology notes

• Market ForecastBottom-up Patient Model

  Estimate ATTR sales potential by diagnosis rates, prevalence, treatment penetration, and drug share.

  The report says that by updating the new patient-base model, it raised AZN’s 2036e Wainua and cliramitug forecasts and cross-validated them with prescription data.

• Market ForecastTop-down Prescription Data Validation

  Use U.S. prescription data to validate patient-model and sales-ramp assumptions.

  This method is used to confirm whether Wainua’s ramp can match Amvuttra and to assess internal-product substitution risk at Alnylam.

• Clinical and Competitive AnalysisMechanism Layering Comparison

  Classify ATTR disease-modifying therapy into stabilizers, silencers, and removers.

  The report argues that AstraZeneca’s coverage of all three mechanisms is a key differentiation versus Alnylam, Pfizer, and BridgeBio.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AstraZeneca PLC / AZN.LN

  Primary beneficiary

  Strengths

  Has Wainua, cliramitug, and commercialization rights for Attruby in Japan, covering three mechanisms: stabilizer, silencer, and remover; the Alexion rare-disease platform provides doctor awareness and execution advantages; CardioTTRansform is a large phase 3 study.

  Weaknesses

  Wainua is still waiting for critical phase 3 data in 2H26; current market consensus on peak sales remains materially below company guidance and Bernstein expectations.

  Comparison

  Compared with Alnylam, AZN has a more complete portfolio; compared with Pfizer and BridgeBio, AZN has a stronger rare-disease platform and potential differentiation through a remover mechanism.

  Risks

  Key phase 3 data may miss expectations, combination-therapy benefits may not be proven, diagnosis-rate improvement may be slower, and pricing or reimbursement pressure may rise.

• Alnylam / ALNY

  Primary competitor

  Strengths

  Amvuttra is a strong first-in-market gene-silencing drug and is currently listed, with consensus peak sales around $9.0bn; nucresiran could offer once-every-six-months dosing convenience.

  Weaknesses

  The report suggests nucresiran is more likely to cannibalize Amvuttra rather than add incremental value; Amvuttra is also subject to royalty obligations to Sanofi.

  Comparison

  First-mover advantage is strong, but its mechanism coverage is less complete than AZN’s, and follow-on products may cause internal substitution.

  Risks

  Share could be ceded to Wainua data and AZN’s combination-therapy strategy; nucresiran commercialization could cannibalize Amvuttra.

• Pfizer / Vyndaquel,Vyndamax

  Incumbent stabilizer-market leader

  Strengths

  Oral administration and favorable tolerability make them long-standing standard-of-care options for ATTR-CM and ATTR-PN; Bloomberg consensus peak sales for 2026 are about $6.8bn.

  Weaknesses

  As stabilizers, they do not reduce TTR production or remove existing deposits; they did not receive U.S. approval in ATTR-PN trials.

  Comparison

  Convenience is strong, but the innovation tier is lower than silencers and removers.

  Risks

  Next-generation silencers and removers could change the treatment paradigm and compress share.

• BridgeBio / Attruby

  Stabilizer competitor and AZN Japan commercialization-linked asset

  Strengths

  Oral stabilizer; ATTRibute-CM phase 3 results showed statistical significance; AstraZeneca handles commercialization in Japan.

  Weaknesses

  ATTR-PN program was withdrawn after weaker early-stage data; globally it still faces competition from Vyndaquel and silencers.

  Comparison

  May have a marginal efficacy advantage over Pfizer’s products, but remains a stabilizer mechanism.

  Risks

  Less than expected indication expansion and uncertainty around early-treatment ACT-early readout.

Key data

• ATTR-CM Peak Market Sizeabout $20bnThe report states that the peak size of this cardiac market is around $20bn, with roughly 10% CAGR from 2026e to 2036e.
• 2036e ATTR Treatment Marketover $30bnThe report says that all three disease-modifying therapy classes together support a total ATTR treatment market of over $30bn by 2036e.
• U.S. ATTR-CM Diagnosis Rateabout 25%Low diagnosis rates are a major basis for market expansion and new-drug penetration.
• G8 ATTR-CM Patient Countabout 800kThe report says there are about 800k ATTR-CM patients in the G8.
• Global Diagnosed ATTR-CM Patientsabout 121kAstraZeneca estimates around 121k globally diagnosed ATTR-CM patients.
• Global Potential ATTR-CM Prevalenceover 900kThe report cites AstraZeneca’s estimate that potential ATTR-CM prevalence is above 900k.
• Wainua 2036e Forecast$6.2bnBernstein raised the 2036e risk-adjusted base-case forecast by 20% to $6.2bn.
• cliramitug 2036e Forecast$3.3bnBernstein raised the 2036e risk-adjusted base-case forecast for cliramitug by roughly 4x to $3.3bn.
• Wainua Bull Case$8.5bnIf CardioTTRansform shows Wainua is more effective in pre-treated patients, the 2036e forecast could rise to $8.5bn, implying 34% market share.
• Vyndaquel Peak Sales$6.8bnBloomberg consensus estimates peak sales of about $6.8bn in 2026.
• Attruby Peak Sales$3.8bnBloomberg consensus estimates peak sales of about $3.8bn in 2035.

Impact & implications

If the report thesis is realized, valuation optionality for AstraZeneca’s non-oncology business and rare-disease platform could increase, with Wainua potentially becoming AZN’s second-largest non-oncology drug and cliramitug’s remover mechanism potentially supporting combo therapy and higher pricing. In the competitive landscape, although Alnylam is the first mover, it may face internal substitution between Amvuttra and nucresiran, while Pfizer and BridgeBio’s stabilizers are positioned earlier stage or in a convenience-first role.

Risks

• CardioTTRansform phase 3 data fail to support Wainua’s best-in-class positioning.
• ATTR-CM diagnosis rates in the U.S. and globally rise too slowly, limiting market expansion.
• Clinical value or commercial feasibility of combination therapy is lower than expected.
• If Alnylam’s nucresiran materially improves convenience, AZN share could be pressured.
• As the first-in-class remover mechanism, cliramitug still has efficacy, safety, and pricing uncertainties.
• Payer reimbursement pressure or price constraints could limit peak sales.

What to watch

• CardioTTRansform phase 3 readout for Wainua in 2H26.
• Phase 3 subgroup readouts in CardioTTRansform for Vyndamax or other pre-treated subsets.
• Commercial progress and phase 3 data for cliramitug around 2029.
• Speed of ATTR-CM diagnosis-rate improvement, especially in the U.S.
• The extent of Amvuttra cannibalization after nucresiran launches in the early 2030s.
• Whether AZN proceeds with combination studies for Wainua maintenance therapy and cliramitug induction therapy.
• Readout of Attruby ACT-early phase 3 project in 2H27.